EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration

Bach Tran Nguyen iD, Julie Bertrand iD, Akosua A Agyeman, Shengyuan Zhang, Ly-Mee Yu iD, Victoria Harris iD, Paul Little iD, Christopher C Butler iD, Judith Breuer iD, David M Lowe iD, Joseph F Standing iD, Jérémie Guedj iD und 1 weitere

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiaf158 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Bach Tran Nguyen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, France. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, Hydroxylamines, Cytidine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gates Foundation, UK Medical Research Council, UK National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The antiviral efficacy of molnupiravir against SARS-CoV-2 is controversial. Here, we develop a model integrating viral and immune dynamics to characterize the mechanism of action of molnupiravir in vivo and its impact on viral dynamics during and after treatment.

Methods

We analyzed data from the PANORAMIC trial, where 577 outpatients were randomized shortly after symptom onset to receive usual care or molnupiravir for 5 days, with viral and immunologic data collected within 2 weeks. We developed a mathematical model that characterized virus-host interaction, accounting for the impact of molnupiravir on viral replication and mutagenesis. The model was used to explore the impact of longer treatment duration.

Results

Molnupiravir reduced RNA replication with an efficacy that reached 93% at the end of a 5-day treatment. This effect was mediated through 2 pathways: 1 that increased transition mutation frequency and 1 that directly inhibited viral production. Accordingly, 5-day treatment shortened the median time to clearance of RNA and infectious virus by approximately 2 days. Ten-day treatment could reduce the time to RNA clearance by 5 days and the occurrence of viral rebounds. Longer treatment durations might be needed for postexposure prophylaxis.

Conclusions

Our model suggests that molnupiravir acts primarily on viral replication, and not specifically on viral infectivity. Longer administration of molnupiravir may reduce the rebound rate, shortening the time to viral clearance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsSARS-CoV-2HydroxylaminesCytidineCOVID-19 Drug TreatmentHumansVirus ReplicationCOVID-19OutpatientsModels, TheoreticalRNA, Viral

Stichwörter der Autor:innen

SARS-CoV-2molnupiravirmutagenesistreatment durationviral clearance

Substanzen

molnupiravirAntiviral AgentsHydroxylaminesCytidineRNA, Viral

Autor:innen und Institutionen

  • Université Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, France.
  • Infection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London.
  • Nuffield Department of Primary Care Health Sciences, University of Oxford.
  • Primary Care Research Centre, University of Southampton.
  • Institute for Immunity and Transplantation, University College London.
  • Department of Clinical Immunology, Royal Free London NHS Foundation Trust.

ORCID-Profile: Bach Tran Nguyen, Julie Bertrand, Ly-Mee Yu, Victoria Harris, Paul Little, Christopher C Butler, Judith Breuer, David M Lowe, Joseph F Standing, Jérémie Guedj

Förderung

  • Gates Foundation
  • UK Medical Research Council
  • UK National Institute for Health and Care Research
  • Bill & Melinda Gates Foundation

Zitieren

APA

Nguyen, B. T., Bertrand, J., Agyeman, A. A., Zhang, S., Yu, L. M., Harris, V., Little, P., Butler, C. C., Breuer, J., Lowe, D. M., Standing, J. F., Guedj, J., & PANORAMIC study group (2025). A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf158

Vancouver

Nguyen BT, Bertrand J, Agyeman AA, Zhang S, Yu LM, Harris V, et al. A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf158

BibTeX
@article{Nguyen2025,
  author = {Nguyen, Bach Tran and Bertrand, Julie and Agyeman, Akosua A and Zhang, Shengyuan and Yu, Ly-Mee and Harris, Victoria and Little, Paul and Butler, Christopher C and Breuer, Judith and Lowe, David M and Standing, Joseph F and Guedj, Jérémie and PANORAMIC study group, PANORAMIC study group},
  title = {A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf158}
}
Kostenlos starten →